- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 8th, 2007
Emerging specialty pharmaceutical company Nanotherapeutics will be using its nanoparticle drug delivery technology to develop an HIV oral peptide vaccine after entering into a two year agreement with the National Cancer Institute (NCI).
The Florida-based company will use its proprietary NanoDRY drug delivery technology to develop the peptide vaccine candidate into an oral form which will have targeted delivery to the lower gastrointestinal (GI) tract.
|Related News Press|
New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015
Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27th, 2015
Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015
New technique speeds nanoMRI imaging: Multiplexing technique for nanoscale magnetic resonance imaging developed by researchers in Switzerland cuts normal scan time from two weeks to two days May 28th, 2015
Squeezed quantum cats May 28th, 2015